$2.830
-0.078 (-2.75%)At close
NSRX Comparative Benchmarking
In the context of the broader market, NSRX competes directly with industry leaders such as PTHS and EDSA. With a market capitalization of $33.14M, it holds a significant position in the sector. When comparing efficiency, NSRX's gross margin of N/A stands against PTHS's 70.18% and EDSA's N/A. Such benchmarking helps identify whether Nasus Pharma Ltd is trading at a premium or discount relative to its financial performance.
Nasus Pharma Ltd Financial Performance
Nasus Pharma has reported increasing net losses, with a net loss of $5.9 million for 2025, compared to $1.5 million in 2024. However, the company has improved its cash position significantly, with cash and equivalents totaling $4.3 million as of December 31, 2025, up from $0.3 million the previous year.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.